Nantes research on astatine in the spotlight
Nantes research on astatine in the spotlight Astatine (At) is the rarest chemical element on Earth, and its 211 isotope is very promising for applications in targeted radiotherapy of cancers. [...]
ILIAD brings together medical, scientific and technological expertise while combining different disciplines (nuclear medicine, oncology, hematology, biological sciences, human and social sciences, epidemiology, chemistry, physics and mathematics) within a consortium of 9 research laboratories, 3 health establishments and 27 high level technological platforms.
ILIAD is underpinned by integrated research, which is innovative and multidisciplinary, structured around heterogeneity and tumour resistance. Articulated around the care pathway, the research carried out by the ILIAD teams also relates to the life of the patients by integrating the issues of social inequality and how to retain a job when faced with illness.
The research programmes are represented by two tumours which have been chosen as demonstrators: multiple myeloma and breast cancer.
Program 1
Developing nuclear medicine tools in order to predict the prognosis and elaborate innovative targeted and personalised therapies.
Programme 2
Developing functional personalised medicine tools combining predictive algorithms and cellular tests.
